Combining targeted radionuclide therapy and cancer immunotherapy to advance precision medicine through innovation.

Medicine & Life Sciences

1. Single-Domain Antibodies 100%
2. Radioisotopes 48%
3. Actinium-225 30%
4. Tumor Microenvironment 20%
5. Immunomodulation 17%
6. Histocompatibility Antigens Class II 16%
7. Melanoma 15%
8. Ligands 14%
9. Lutetium-177 13%
10. T-Lymphocytes 12%
11. Natural Killer T-Cells 10%
12. Vaccination 10%
13. Posters 9%
14. Immunoglobulin Fragments 9%
15. Therapeutics 9%
16. Single-Photon Emission-Computed Tomography 7%
17. Neoplasms 7%
18. Multiple Myeloma 7%
19. Ovalbumin 7%
20. Vaccines 6%
21. Tomography 5%